Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
FOXO4-DRI is among the highest-risk research peptides from an evidence-to-risk standpoint: it has never been tested in humans, no human pharmacokinetic data exists, and as a senolytic it carries theoretical risks specific to its mechanism
Our knowledge is both theoretical and practical, and its always growing
Source List Peer-Reviewed & Established Academic Sources Only PMC / NIH Pickart L
Most users report visible improvements starting around 8 to 12 weeks of consistent injectable use, with optimal results building over 12 or more weeks of continuous administration
US$ 24.35
US$ 25.30
US$ 25.90
US$ 27.88
US$ 26.20
US$ 29.49
US$ 27.37
